TrialsgrambetaRCTs are beautiful

SMART

2006

Salmeterol Multicenter Asthma Research Trial

In 26,355 patients with asthma, salmeterol added to usual care increased respiratory-related and asthma-related mortality compared with placebo plus usual care.

Result

Efficacy: Respiratory- and asthma-related death/life-threatening eventRR 2.16

Below 1 favours salmeterol added to usual care, above 1 favours placebo plus usual care.

Event rates Salmeterol added to usual care 24 vs placebo plus usual care 11 events

Also reported: Asthma deaths 13 vs 3. Excess concentrated in African-Americans and ICS-naïve patients.

Original publication
Subtopic
LABA safety
Design
Multicentre RCT, USA
Relevance
Practice-defining: a trial the field needs to know.
Source
Nelson HS, et al. Chest. 2006;129(1):15-26.doi 10.1378/chest.129.1.15

Discussion & critique

Triggered the FDA LABA black-box warning and the modern rule that LABAs must be combined with ICS in asthma.